Literature DB >> 12922128

A highly infective Plasmodium vivax strain adapted to Aotus monkeys: quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development.

Yago Pico de Coaña1, Josefa Rodríguez, Eduar Guerrero, Carlos Barrero, Raúl Rodríguez, Marcela Mendoza, Manuel Alfonso Patarroyo.   

Abstract

The New World primate Aotus nancymaae is susceptible to infection by the human malaria parasite Plasmodium vivax and has therefore been recommended by the World Health Organization as a model for malaria vaccine candidate evaluation. We report the isolation, adaptation, titration and genetic characterization of a P. vivax wild strain in splenectomized A. nancymaae monkeys. Parasitemia remained high after 22 passages, reaching 7.88% by Giemsa and Acridine Orange staining and Real-Time PCR determination, making this P. vivax strain a highly infective and reliable asset to be used in P. vivax biological studies and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922128     DOI: 10.1016/s0264-410x(03)00278-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Reference strand conformational analysis (RSCA) is a valuable tool in identifying MHC-DRB sequences in three species of Aotus monkeys.

Authors:  Juan E Baquero; Santiago Miranda; Oscar Murillo; Heidy Mateus; Esperanza Trujillo; Carlos Suarez; Manuel E Patarroyo; Carlos Parra-López
Journal:  Immunogenetics       Date:  2006-05-30       Impact factor: 2.846

2.  Owl monkey MHC-DRB exon 2 reveals high similarity with several HLA-DRB lineages.

Authors:  Carlos F Suárez; Manuel E Patarroyo; Esperanza Trujillo; Mónica Estupiñán; Juan E Baquero; Carlos Parra; Raúl Rodriguez
Journal:  Immunogenetics       Date:  2006-06-22       Impact factor: 2.846

3.  Comparative molecular and three-dimensional analysis of the peptide-MHC II binding region in both human and Aotus MHC-DRB molecules confirms their usefulness in antimalarial vaccine development.

Authors:  M E Patarroyo; G Cifuentes; J Baquero
Journal:  Immunogenetics       Date:  2006-06-22       Impact factor: 2.846

4.  PvRON2, a new Plasmodium vivax rhoptry neck antigen.

Authors:  Gabriela Arévalo-Pinzón; Hernando Curtidor; Liliana C Patiño; Manuel A Patarroyo
Journal:  Malar J       Date:  2011-03-14       Impact factor: 2.979

5.  Identification and characterization of the Plasmodium vivax thrombospondin-related apical merozoite protein.

Authors:  Alvaro Mongui; Diana I Angel; Darwin A Moreno-Perez; Silvana Villarreal-Gonzalez; Hannia Almonacid; Magnolia Vanegas; Manuel A Patarroyo
Journal:  Malar J       Date:  2010-10-13       Impact factor: 2.979

6.  Identification, characterization and antigenicity of the Plasmodium vivax rhoptry neck protein 1 (PvRON1).

Authors:  Darwin A Moreno-Perez; Marjorie Montenegro; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  Malar J       Date:  2011-10-24       Impact factor: 2.979

7.  The Plasmodium vivax rhoptry neck protein 5 is expressed in the apical pole of Plasmodium vivax VCG-1 strain schizonts and binds to human reticulocytes.

Authors:  Gabriela Arévalo-Pinzón; Maritza Bermúdez; Hernando Curtidor; Manuel A Patarroyo
Journal:  Malar J       Date:  2015-03-07       Impact factor: 2.979

8.  Characterizing PvARP, a novel Plasmodium vivax antigen.

Authors:  Darwin A Moreno-Pérez; Ambar Saldarriaga; Manuel A Patarroyo
Journal:  Malar J       Date:  2013-05-20       Impact factor: 2.979

Review 9.  Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines.

Authors:  M E Patarroyo; G Cifuentes; A Bermúdez; M A Patarroyo
Journal:  J Cell Mol Med       Date:  2008-10       Impact factor: 5.310

10.  Annotation and characterization of the Plasmodium vivax rhoptry neck protein 4 (PvRON4).

Authors:  Gabriela Arévalo-Pinzón; Hernando Curtidor; Jesica Abril; Manuel A Patarroyo
Journal:  Malar J       Date:  2013-10-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.